NCT01688947

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 105 (actual)
• Sponsor: Purdue Pharma LP · Industry
• Sex: All
• Age: 21 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the analgesic efficacy of 2 dose levels of V116517 versus placebo.

Conditions

• Postherpetic Neuralgia
• Pain

Interventions

Type	Name	Description
DRUG	V116517 50-mg tablets	Taken orally twice daily
DRUG	V116517 30-mg tablets	Taken orally twice daily
DRUG	Pregabalin capsules	1-2 capsules taken orally twice daily
DRUG	Placebo	Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily

Timeline

• Start date: 2012-09-01
• Primary completion: 2014-03-01
• Completion: 2014-04-01
• First posted: 2012-09-20
• Last updated: 2014-05-12

Locations

28 sites across 1 country: United States